ストックスクリーナーアプリを入手
4.33
0.00%
0.00
アフターアワーズ：
4.35
0.02
+0.46%
前日終値:
$4.33
開ける：
$4.4
24時間の取引高:
674.48K
Relative Volume:
1.06
時価総額：
$363.76M
収益：
$70.14M
当期純損益:
$-76.24M
株価収益率:
-5.0941
EPS:
-0.85
ネットキャッシュフロー:
$-57.06M
1週間 パフォーマンス:
+15.78%
1か月 パフォーマンス:
+31.61%
6か月 パフォーマンス:
+23.36%
1年 パフォーマンス:
+125.52%
1日の値動き範囲:
$4.295
$4.525
1週間の範囲:
$3.70
$4.525
52週間の値動き範囲:
$1.85
$4.91
Codexis Inc Stock (CDXS) Company Profile
CDXS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| CDXS | 4.33 | 363.76M | 70.14M | -76.24M | -57.06M | -0.85 |
| VRTX | 450.37 | 115.10B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.74 | 35.07B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.80 | 32.20B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.23 | 25.09B | 3.30B | -501.07M | 1.03B | 11.54 |
Codexis Inc Stock (CDXS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-05-09 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | 再開されました | Piper Sandler | Overweight |
| 2022-03-02 | 再開されました | Cowen | Outperform |
| 2021-04-12 | 開始されました | Piper Sandler | Overweight |
| 2021-03-01 | 開始されました | Stifel | Buy |
| 2021-02-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-10 | 開始されました | The Benchmark Company | Buy |
| 2019-01-17 | アップグレード | First Analysis Sec | Neutral → Outperform |
| 2018-05-16 | 開始されました | Stephens | Overweight |
| 2017-10-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-05-31 | 開始されました | Jefferies | Buy |
| 2017-01-26 | ダウングレード | First Analysis Sec | Overweight → Equal-Weight |
| 2017-01-04 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2016-01-06 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Codexis Inc (CDXS) 最新ニュース
Codexis (STU:4QK) 3-Year FCF Growth Rate : -35.00% (As of Sep. 2024) - GuruFocus.com
Codexis (STU:4QK) Forward Dividend Yield % : 0.00% (As of Nov. 20, 2024) - GuruFocus.com
Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
Codexis to Present at Piper Sandler Healthcare Conference in December 2024 | CDXS Stock News - StockTitan
Codexis (NASDAQ:CDXS) Given Overweight Rating at Cantor Fitzgerald - MarketBeat
Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics - GlobeNewswire
Codexis Achieves 98% Efficiency in Breakthrough siRNA Synthesis Platform | CDXS Stock News - StockTitan
Baillie Gifford & Co. Sells 895,002 Shares of Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
Codexis adds biotech veteran Raymond De Vré to board - Investing.com India
Codexis Strengthens Board and Updates Bylaws - TipRanks
CDXSCodexis, Inc. Latest Stock News & Market Updates - StockTitan
Codexis adds biotech veteran Raymond De Vré to board By Investing.com - Investing.com UK
Codexis Announces Appointment of Raymond De Vré, PhD, to Board of Directors - GlobeNewswire
Codexis Strengthens Board with Biotech Veteran Raymond De Vré, Former PolyPeptide CEO | CDXS Stock News - StockTitan
Biofuel Enzymes Market Growth Surge: Key Players and Market - openPR
Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics - GlobeNewswire
Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for - The Bakersfield Californian
Codexis to Showcase Breakthrough RNA Platform, Partners with Bachem at TIDES Europe 2024 | CDXS Stock News - StockTitan
Codexis Announces New Employment Inducement Grants - The Manila Times
Codexis, Inc.'s (NASDAQ:CDXS) 29% Jump Shows Its Popularity With Investors - Simply Wall St
Benchmark Downgrades Codexis (CDXS) - MSN
CDXS (Codexis) PE Ratio : At Loss (As of Nov. 06, 2024) - GuruFocus.com
Codexis (FRA:4QK) 3-Year EBITDA Growth Rate : -26.40% (As of Sep. 2024) - GuruFocus.com
Benchmark Reaffirms “Hold” Rating for Codexis (NASDAQ:CDXS) - Defense World
Codexis's SWOT analysis: enzyme engineering firm pivots to RNAi stock By Investing.com - Investing.com Australia
abrdn plc Grows Stock Holdings in Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
Codexis's SWOT analysis: enzyme engineering firm pivots to RNAi stock - Investing.com India
Codexis to Participate in Upcoming Healthcare Conferences - The Manila Times
Codexis (NASDAQ:CDXS) Earns Hold Rating from Benchmark - MarketBeat
Codexis, Inc. (NASDAQ:CDXS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$7.17 - Yahoo Finance
Codexis, Inc. Announces Strong Third Quarter 2024 Financial Results - Defense World
Codexis Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
Codexis (CDXS) Reports Q3 Loss, Tops Revenue Estimates - MSN
Codexis, Inc. (NASDAQ:CDXS) Q3 2024 Earnings Call Transcript - Insider Monkey
Codexis Inc (CDXS) Q3 2024 Earnings Call Highlights: Strong Reve - GuruFocus.com
Earnings call: Codexis reports revenue growth and strategic focus in Q3 2024 - Investing.com
Codexis Inc Q3 2024 Earnings: Revenue Hits $12.83M, Beating Esti - GuruFocus.com
Codexis Inc (CDXS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Focus ... - Yahoo Finance
Codexis Reports Strong Q3 Revenue Growth - TipRanks
Codexis: Q3 Earnings Snapshot - CT Insider
Codexis Reports Third Quarter 2024 Financial Results - The Manila Times
Codexis Inc (CDXS) 財務データ
収益
当期純利益
現金流量
EPS
0.93%
3.56%
大文字化:
|
ボリューム (24 時間):